Experimental Drug Combination Cleared Tumors in Mice And Left Them Resistant to The Same Cancer
Key Points:
- Researchers at Regeneron Pharmaceuticals demonstrated in mice that combining the cancer drug Enhertu (trastuzumab deruxtecan) with an experimental bispecific antibody can eliminate tumors and induce lasting immune memory, enabling resistance to tumor re-injection without further treatment.
- The experimental antibody targets both tumor cells and the T cell activation protein CD28, enhancing T cell responses essential for tumor elimination; removal of CD8 T cells abolished the treatment's benefit, highlighting their critical role.
- Additional tests showed the combination increased T cell receptor diversity and activated dendritic cells, improving immune recognition of cancer, while combinations with chemotherapy (5-FU) also engaged natural killer cells to slow tumor growth.
- The study's mouse models cannot fully predict human side effects or treatment safety, and further clinical evaluation is needed; Regeneron funded the research, with all authors affiliated and patent applications filed related to the work.